Figure 6: Example results for a patient who received chemotherapy with docetaxel. The patient was 50-year-old male with a biopsy-proven prostate cancer Gleason score of 10 and a PSA level of 110 ng ml−1 . MRI showed prostate cancer accompanied by enlarged pelvic lymph nodes and bone scan showed no metastatic bone lesions. The patient was ready to undergo salvage RP, but the therapeutic strategy was changed after PSMA-SPECT/CT imaging showed multiple metastatic lesions (a) in the pelvis, (b) prostate cancer, (c) near to the iliac blood vessels and at (a and d) vertebrae and (e) mediastinal sites. The patient received chemotherapy with docetaxel and his PSA level decreased to 3 ng ml−1 . The metastatic lesions are indicated by arrows.